The advent of immunotherapy has proven to be a gamechanger in cancer treatment. However, predicting a patient’s responsiveness to a given treatment regimen can be tricky and can cause serious side effects. A study has identified biomarkers in non-small cell lung cancer (NSCLC) patients which can help determine their response to immunotherapy.
Researchers analyzed blood samples of 29 NSCLC patients and found that individuals with elevated levels of a T-cell differentiation marker named “ CX3CR1 ” showed a better response to chemoimmunotherapy at six and eight weeks, with improved prognosis as well . In 83.3% patients responsive to the therapy, at least 10% increase from baseline was observed in CX3CR1 + CD8 T-cells, while only 2 out of 19 non-responsive patients showed such elevation. The findings from this study can help significantly improve the patient selection procedure for…
